Trade Mark Journal No.2026/014 3 April 2026

UK00004355478 16 March 2026 (5,42)

CTX611

International priority date claimed: 7 January 2026 (United States of America) (99583006)

Class 5: Cells for medical or clinical use in the field of gene therapy for the treatment of cardiovascular diseases and thromboembolic diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular diseases and thromboembolic diseases and disorders in the field of gene therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular diseases and thromboembolic diseases and disorders in the field of gene therapy.
Class 42: Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of gene therapy.

CRISPR Therapeutics AG

Representative: HGF Limited